DNA
Ginkgo Bioworks Holdings
11.50$
-7.6%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
Ginkgo Bioworks Holdings (DNA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -44 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -24 | -27 | -25 | -59 | -48 | -35 | -5.2 | -166 | -20 | -99 | -28 | -105 | -91 | -74 | -74 | -58 | -89 | -84 | -104 | -42 | -52 | -40 | -32 | -48 | -47 | -44 | -170 | |
| 3.2 | 3.2 | 3.5 | 4.0 | 5.6 | 7.2 | 8.3 | 8.0 | 9.5 | 9.6 | 8.9 | 18 | 27 | 26 | 21 | 13 | 13 | 17 | 17 | 16 | 15 | 16 | 14 | 14 | 13 | 12 | 53 | |
| 0.1 | 0.1 | – | 0.1 | 0.1 | 15 | 0.1 | 1,591 | 653 | 607 | 563 | 118 | 73 | 61 | 53 | 43 | 41 | 37 | 14 | 21 | 20 | 22 | 18 | 21 | 16 | 7.6 | 62 | |
| 8.9 | -2.5 | 0.2 | – | -9.5 | 102 | 6.5 | 1,519 | 572 | 635 | 588 | 65 | 81 | 93 | 211 | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.4 | 2.2 | – | -13 | 3.1 | 2.5 | 20 | -92 | -10 | -53 | 34 | -7.9 | 1.5 | -12 | -1.8 | 42 | 0.3 | 5.9 | -98 | 2.2 | -12 | -23 | 14 | -24 | -14 | -13 | -37 | |
| 3.3 | 6.5 | 29 | 19 | 22 | 24 | 5.4 | 5.1 | 3.6 | 9.6 | 13 | 26 | 19 | 14 | 4.4 | 3.4 | 6.7 | 27 | 15 | 14 | 7.6 | 0.0 | 7.7 | 15 | 1.9 | 2.6 | 28 | |
| -3.3 | -6.5 | -29 | -29 | -23 | -24 | -31 | 4.2 | -36 | -15 | -46 | 30 | -19 | -11 | -3.4 | -47 | -12 | -27 | -10 | -13 | -199 | -64 | -73 | 95 | 23 | 11 | 57 | |
| – | – | – | – | – | – | – | 25 | – | – | – | – | – | 0.6 | – | 0.6 | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | 1,754 | 1,754 | -892 | -9.5 | -1.0 | -0.1 | 0.0 | -1.0 | 0.0 | 0.0 | – | 0.0 | – | – | 0.1 | 0.1 | 0.0 | 0.0 | 10 | 19 | – | – | – | |
| -0.2 | -0.2 | -0.2 | – | -0.3 | 0.3 | -0.3 | -0.4 | -0.3 | -0.4 | -0.1 | 98 | -0.6 | -0.3 | -0.3 | – | – | – | -0.2 | -0.2 | -0.2 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | |
| -3.6 | 72 | 22 | -0.2 | -0.4 | -2.1 | 1,548 | -11 | -1.2 | -1.0 | -0.3 | 98 | -0.9 | -1.4 | -0.3 | -0.6 | -0.8 | -0.2 | -0.5 | -0.2 | -0.2 | -0.1 | 9.9 | 8.1 | 0.0 | 16 | 35 | |
| -31 | 38 | -32 | -88 | -379 | -1.9 | 1,512 | -189 | -55 | -114 | -72 | 24 | -110 | -86 | -77 | -104 | -105 | -111 | -114 | -56 | -250 | -106 | -94 | 54 | -24 | -17 | -80 | |
| -27 | -34 | – | -79 | -70 | -59 | -11 | -171 | -23 | -109 | -42 | -130 | -110 | -87 | -78 | -61 | -96 | -111 | -119 | -56 | -59 | -40 | -32 | -63 | -49 | -47 | -190 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.